Patents by Inventor Katia Dimitrova Karamfilova

Katia Dimitrova Karamfilova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiroheterocyclic compounds as mGlu5 antagonists
    Patent number: 8580962
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 12, 2013
    Assignee: Recordati Ireland Ltd.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Davide Graziani, Carlo De Toma, Katia Dimitrova Karamfilova
  • NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS
    Publication number: 20120059015
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Application
    Filed: July 11, 2011
    Publication date: March 8, 2012
    Applicant: Recordati Ireland Ltd.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Davide Graziani, Carlo De Toma, Katia Dimitrova Karamfilova